Mise au point sur Medscape

Defining Treatment Failure and Success in Rheumatoid Arthritis and Practical Applications of New Biologics
Daniel Furst, MD, Chair; Mark Genovese, MD; Joel Kremer, MD; Steven Abramson, MD; Eric Ruderman, MD
This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Defining Treatment Failure in Rheumatoid Arthritis and Practical Applications of New Biologics" symposium held in Washington, DC, on November 14, 2006.

Contents of This CME Activity
Welcome and IntroductionDaniel Furst, MDAvailable As: Slides/Audio | Slides/Transcript | Audio

Basing Your Treatment Decision on the Latest Evidence From Clinical Trials With Biologics: Can We Tell the Biologics Apart?Mark Genovese, MDAvailable As: Slides/Audio | Slides/Transcript | Audio

Improving Outcomes in RA: When Is It Time to Start Using Biologic Agents?Joel Kremer, MDAvailable As: Slides/Audio | Slides/Transcript | Audio

The Patient Who Fails TNF-Blockers: What Next?Steven Abramson, MDAvailable As: Slides/Audio | Slides/Transcript | Audio

Which Biologic Should Be Used When: Can We Figure Out Who Is a Treatment Failure, and What Can We Do About It?Eric Ruderman, MDAvailable As: Slides/Audio | Slides/Transcript | Audio

Abstracts

http://www.medscape.com/viewprogram/6721?sssdmh=dm1.252021&src=nlcmealert